Standout Papers

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer... 2006 2026 2012 2019 2.8k
  1. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer (2009)
    Eric Van Cutsem, Claus-Henning Köhne et al. New England Journal of Medicine
  2. KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer (2006)
    Astrid Lièvre, Jean‐Baptiste Bachet et al. Cancer Research
  3. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial (2014)
    H. Wilke, Kei Muro et al. The Lancet Oncology
  4. Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status (2011)
    Eric Van Cutsem, Claus-Henning Köhne et al. Journal of Clinical Oncology
  5. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial (2008)
    Bernard Nordlinger, Halfdan Sørbye et al. The Lancet
  6. KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab (2008)
    Astrid Lièvre, Jean‐Baptiste Bachet et al. Journal of Clinical Oncology
  7. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial (2013)
    Bernard Nordlinger, Halfdan Sørbye et al. The Lancet Oncology
  8. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. (1998)
    Philippe Rougier, Marc Buyse et al. Journal of Clinical Oncology
  9. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer (1998)
    Philippe Rougier, Eric Van Cutsem et al. The Lancet
  10. Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer (2015)
    Eric Van Cutsem, Heinz‐Josef Lenz et al. Journal of Clinical Oncology
  11. Analysis of PTEN , BRAF , and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer (2009)
    Pierre Laurent‐Puig, Anne Cayre et al. Journal of Clinical Oncology
  12. Influence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver Metastases (2005)
    Mehdi Karoui, Christophe Penna et al. Annals of Surgery
  13. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma (1985)
    Maurice Tubiana, Martin Schlumberger et al. Cancer
  14. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials (2012)
    Carsten Bokemeyer, Eric Van Cutsem et al. European Journal of Cancer
  15. Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus (2015)
    René Adam, Aimery de Gramont et al. Cancer Treatment Reviews

Immediate Impact

5 by Nobel laureates 3 from Science/Nature 194 standout
Sub-graph 1 of 13

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Colorectal cancer
2024 Standout
59 intermediate papers

Works of Philippe Rougier being referenced

Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial
2013 Standout
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
2008 Standout
and 19 more

Author Peers

Author Last Decade Papers Cites
Philippe Rougier 17070 7242 4911 6459 128 21.9k
Valérie Boige 9238 6005 5539 3856 282 17.2k
Werner Scheithauer 14209 5302 4053 4496 346 17.8k
Marc Ychou 15774 7558 4736 2857 319 21.6k
Olivier Bouché 18148 9242 7789 2968 410 24.6k
Jordan Berlin 15107 6177 3357 2723 351 22.4k
Yoon‐Koo Kang 11984 13225 6704 4096 543 25.4k
Ian Chau 12763 6982 5277 3130 463 18.2k
Aimery de Gramont 19720 6646 5217 4641 332 24.4k
Jinru Shia 12327 3852 6614 2046 367 18.5k
Christophe Louvet 14592 5964 4101 3574 278 17.4k

All Works

Loading papers...

Rankless by CCL
2026